Biogen and Denali report that their Parkinson's disease drug did not meet the trial endpoint
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The two pharmaceutical companies said on Thursday that, in light of the trial results, they will halt further development of BIIB122 for the treatment of idiopathic Parkinson's disease. Denali's share price fell 7% to $18, while Biogen's share price dipped 1% to $187.49. BIIB122 is currently in a phase 2b trial aimed at treating early-stage Parkinson's disease, but the study failed to meet its primary or secondary endpoints.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Federal Reserve Governor Waller: Inflation Risk Means Fed Should No Longer Signal Rate Cuts
BlockBeats•2026/05/22 14:06
Dell surges over 13% to a record high, with a nearly 130% gain year-to-date
格隆汇•2026/05/22 13:59
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$76,988.96
-0.02%
Ethereum
ETH
$2,119.85
+0.17%
Tether USDt
USDT
$0.9989
-0.01%
BNB
BNB
$662.4
+2.03%
XRP
XRP
$1.36
-0.12%
USDC
USDC
$0.9997
-0.00%
Solana
SOL
$86.88
+0.90%
TRON
TRX
$0.3597
-0.62%
Dogecoin
DOGE
$0.1060
+1.44%
Hyperliquid
HYPE
$61.05
+2.91%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now